Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
Deininger, Michael W
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. [electronic resource] - Blood Feb 2016 - 703-12 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
1528-0020
10.1182/blood-2015-08-660977 doi
Amino Acid Substitution
Chemotherapy, Adjuvant
DNA Mutational Analysis--methods
Drug Resistance, Neoplasm--genetics
Fusion Proteins, bcr-abl--genetics
High-Throughput Nucleotide Sequencing
Humans
Imidazoles--therapeutic use
Leukemia, Myeloid, Chronic-Phase--drug therapy
Mutation--physiology
Neoadjuvant Therapy
Protein Kinase Inhibitors--therapeutic use
Pyridazines--therapeutic use
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. [electronic resource] - Blood Feb 2016 - 703-12 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
1528-0020
10.1182/blood-2015-08-660977 doi
Amino Acid Substitution
Chemotherapy, Adjuvant
DNA Mutational Analysis--methods
Drug Resistance, Neoplasm--genetics
Fusion Proteins, bcr-abl--genetics
High-Throughput Nucleotide Sequencing
Humans
Imidazoles--therapeutic use
Leukemia, Myeloid, Chronic-Phase--drug therapy
Mutation--physiology
Neoadjuvant Therapy
Protein Kinase Inhibitors--therapeutic use
Pyridazines--therapeutic use